A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast and Gynecologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs AB-928 (Primary) ; Doxorubicin liposomal (Primary) ; IPI 549 (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Arcus Biosciences
- 23 Sep 2019 According to an Arcus Biosciences media release, data from this trial will be presented in a poster display session at the 2019 European Society for Medical Oncology (ESMO) Annual Meeting (Barcelona, Spain from 27th Sep-1st Oct 2019).
- 06 Aug 2019 According to an Arcus Biosciences media release, company anticipates to initiate safety dose-escalation part in combination with PLD and IPI-549 in 2H 2019.
- 31 Jul 2019 Planned End Date changed from 30 Dec 2021 to 30 Jul 2022.